FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial  by Mortensen, Lise Saksø et al.
Radiotherapy and Oncology 105 (2012) 14–20Contents lists available at SciVerse ScienceDirect
Radiotherapy and Oncology
journal homepage: www.thegreenjournal .comPET imaging of hypoxia
FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the
head and neck treated with radiotherapy: Results from the DAHANCA 24 trial
Lise Saksø Mortensen a,⇑, Jørgen Johansen b, Jesper Kallehauge a, Hanne Primdahl a, Morten Busk a,
Pernille Lassen a, Jan Alsner a, Brita S. Sørensen a, Kasper Toustrup a, Steen Jakobsen a, Jørgen Petersen a,
Henrik Petersen b, Jørn Theil a, Marianne Nordsmark a, Jens Overgaard a
aAarhus University Hospital (AUH); and bOdense University Hospital (OUH), Denmark
a r t i c l e i n f o a b s t r a c tArticle history:
Received 5 June 2012
Received in revised form 22 September 2012
Accepted 22 September 2012
Available online 16 October 2012
Keywords:
Hypoxia
18F-FAZA
18F-ﬂuoroazomycin arabinoside
PET
HPV
Head and neck cancer
Outcome0167-8140 2012 Elsevier Ireland Ltd.
http://dx.doi.org/10.1016/j.radonc.2012.09.015
⇑ Corresponding author. Address: Department of Ex
Aarhus University Hospital, Nørrebrogade 44, Bldg. 5
E-mail address: lsm@oncology.dk (L.S. Mortensen)
Open access undPurpose: Hypoxia is a cause of resistance to radiotherapy, especially in patients with head and neck squa-
mous cell carcinoma (HNSCC). The purpose of this study was to evaluate 18F-ﬂuoroazomycin arabinoside
(FAZA) positron emission tomography (PET)/computed tomography (CT) hypoxia imaging as a prognostic
factor in HNSCC patients receiving radiotherapy.
Material and methods: Forty patients with HNSCC treated with radiotherapy (66–76 Gy) were included.
Static FAZA PET/CT imaging 2 h post injection was conducted prior to irradiation. The hypoxic volume
(HV) was delineated using a tumor-to-muscle value P1.4. In 13 patients, a repetitive FAZA PET/CT scan
was conducted during the radiotherapy treatment.
Results: A hypoxic volume could be identiﬁed in 25 (63%) of the 40 tumors. FAZA PET HV varied consid-
erably with a range from 0.0 to 30.9 (median: 0.3) cm3. The Tmax/Mmed ranged from 1.1 to 2.9 (median:
1.5). The distribution of hypoxia among the Human Papillomavirus (HPV) positive (12/16) and negative
(13/24) tumors was not signiﬁcant different. In the FAZA PET/CT scans performed during radiotherapy,
hypoxia could be detected in six of the 13 patients. For these six patients the location of HV remained
stable in location during radiotherapy treatment, though the size of the HV decreased. In 30 patients a
positive correlation was detected between maximum FAZA uptake in the primary tumor and the lymph
node. During a median follow up of 19 months a signiﬁcant difference in disease free survival rate with
93% for patients with non hypoxic tumors and 60% for patients with hypoxic tumors could be detected.
Conclusion: This study emphasizes the role of FAZA PET/CT imaging as a suitable assay with prognostic
potential for detection of hypoxia in HNSCC.
 2012 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 105 (2012) 14–20Hypoxic volumes exist in most solid tumors [1]. Hypoxia is a
cause of resistance to radiotherapy; hence, it is an important prog-
nostic factor, which is particularly well-documented in squamous
cell carcinomas of the head and neck (HNSCC) [2]. Modiﬁcation
of tumor hypoxia improves loco-regional control and survival in
patients with HNSCC treated with radiotherapy [3].
One approach to overcome hypoxia in tumors is to increase the
radiation dose selectively to resistant volumes of the tumor by
intensity modulated radiation therapy (IMRT), without increasing
the dose to the normal tissue [4]. In standard radiotherapy treat-
ment, the radiation dose prescribed is based upon morphological
information. HNSCC are however, biologically highly heteroge-
neous tumors containing volumes of diverse radiation resistance.
By integrating biological information it is possible to escalate the
dose exclusively to the more resistant volumes of the tumor. Thisperimental Clinical Oncology,
, DK-8000 Aarhus, Denmark.
.
er CC BY-NC-ND license.is expected to increase disease free survival by improving local
tumor control without compromising the normal tissue. However,
no clinical data have yet conﬁrmed this concept. The search for
reliable and clinical applicable methods to identify tumors that
would beneﬁt from hypoxia targeted therapy is ongoing.
PET imaging with a hypoxia speciﬁc tracer is a non-invasive
method that provides a three-dimensional image of the degree of
hypoxia within the tumor [5]. Consequently, PET imaging of tumor
hypoxia is an obvious method to use for dose escalation of hypoxic
regions within the tumor as PET scans can be repeated to detect
spatial and temporal ﬂuctuations in the hypoxic volumes [6].
Various hypoxia speciﬁc tracers have been tested clinically,
mainly based on nitroimidazoles. Nitroimidazoles are reduced un-
der hypoxia and become bound to cell components in hypoxic cells
only [7]. The ﬁrst tracer to be tested clinically was 18F-ﬂouromison-
idazole (FMISO), which is still the most widely used [8–10]. The
novel hypoxia speciﬁc tracer 18F-ﬂuoroazomycin arabinoside
(FAZA) has generated higher tumor-to-background ratios com-
L.S. Mortensen et al. / Radiotherapy and Oncology 105 (2012) 14–20 15pared to FMISO in preclinical studies [11,12]. This is due to a more
rapid clearance of unbound tracer from non-hypoxic tissues [11],
making FAZA a more attractive tracer for clinical use.
The DAHANCA 24 protocol was initiated with the primary aim
to investigate the prognostic value of FAZA imaging in patients
with HNSCC treated with radiotherapy.
Materials and methods
Patient and tumor data
Forty patients with newly diagnosed HNSCC referred for radio-
therapy were prospectively included in the DAHANCA 24 protocol
between December 2009 and October 2011. Eligibility criteria
were: squamous cell carcinoma (T1-4 N0-N3 M0) of the larynx,
pharynx or oral cavity; age above 17 years; no serious concurrent
medical disease; no other current or prior malignant disease that
could affect the treatment, evaluation or outcome of current dis-
ease; and the patient should be able to complete the treatment
and follow-up. Patients were recruited at Aarhus University Hospi-
tal (n = 27) and Odense University Hospital (n = 13). Thirty-two
males and eight females participated. Tumors were staged on the
basis of clinical examination and relevant imaging modalities. Pa-
tients and tumor characteristics can be seen in Table 1.
The DAHANCA 24 study was approved by the local ethics com-
mittees according to Danish law and regulations. The trial was re-
ported to Clinicaltrials.gov (ID: NCT01017224).Treatment
Treatment was given with curative intent according to the
DAHANCA guidelines (www.dahanca.dk). All forty patients re-
ceived primary radiotherapy combined with the hypoxic cellTable 1
Patient and tumor characteristics as a function of FAZA hypoxia status.
Patient/tumor Data All patients Hypoxicb Non hypoxicb P
(n = 40) (n = 25) (n = 15)
Age (years)
Median 61 61 61
Range (44–80) (44–80) (48–77)
<61 years 18 10 8
P61 years 22 15 7 n.s.a
Gender
Female 8 6 2
Male 32 19 13 n.s.a
Tumor site
Supraglottic larynx 9 4 5
Hypopharynx 3 3 0 n.s.a
Oropharynx 25 15 10
Rhinopharynx 3 3 0
Tumor classiﬁcation
T1-2 28 14 14
T3-4 12 11 1 0.02a
Nodal stage
N0 10 4 6
N1-3 30 21 9 n.s.a
Disease stage
I–II 8 2 6
III–IV 32 23 9 0.04a
Tumor volume (cm3)
Median 15.2 19.5 10.6
Range (1.8–143.7) (4.8–143.7) (1.8–36.6)
>15 cm3 21 15 6
615 cm3 19 10 9 n.s.
The values are in bold as they are the only signiﬁcant values.
n.s., not signiﬁcant.
a Fisher’s exact test for comparison between hypoxic and non hypoxic groups.
b Tumors were separated by FAZA HV.sensitizer nimorazole (1200 mg/m2), and in addition, 22 patients
received weekly concomitant cisplatin (40 mg/m2). No elective
neck dissection was conducted.
Radiotherapy was prescribed in fractions of 2 Gy with a mini-
mum dose of 66–68 Gy, 5–6 fractions per week during 5½–
6½weeks. Tumor size and location determined treatment dose.
One patient (ID7) received accelerated hyperfractionated radio-
therapy (76 Gy, in 56 fractions). All patients, except one (ID 9) re-
ceived the planned treatment.
Follow up was conducted according to the DAHANCA guidelines
with clinical examination at 2 months after completion of radio-
therapy and then every 3 months during the ﬁrst 2 years and every
6 months for the next 3 years. If a recurrence was suspected, con-
ﬁrmative CT or MRI scan was performed. Detailed description of
the treatment is given in Supplementary Table 1.FAZA PET/CT imaging protocol
FAZA was produced as described previously [13]. Twenty-seven
patients were scanned on a Siemens Biograph Truepoint 64 PET/CT
scanner (Siemens, Medical Systems) and for the remaining thirteen
patients the FAZA imaging were obtained using a General Electric
Discovery STE PET/CT scanner (GE Healthcare Technologies). The
non-fasting patients received 365 (range 246–410) MBq FAZA
and were scanned 123 (range 117–137) minutes post injection.
All patients were scanned in one bed position (10 min) on a ﬂat ta-
ble top, positioned by laser, and wearing a rigid mask immobilizing
head, neck, and shoulders. To minimize patient misalignment, the
same procedures for securing the position of the patient were done
when the patients had the contrast-enhanced CT of the head and
neck (planning CT) for the radiation treatment planning. FAZA
emission data were corrected for attenuation, scatter, and random
coincidences following iteratively reconstruction. Calibrations
with a FAZA ﬁlled NEMA phantom were conducted to ensure con-
sistency of measurements between scanners.
The baseline FAZA PET/CT scan was conducted prior to the start
of radiotherapy treatment (median interval 6, range 0–9 days) and
for 13 patients a second FAZA PET/CT scan was conducted during
the radiotherapy. None of the FAZA scans were used for the
radiation treatment plan as evaluation was performed post
treatment.Image evaluation of FAZA
In all patients the primary tumor deﬁned as gross tumor volume
(GTVplanning) from the planning CT was delineated by experienced
radiation oncologists and radiologists. In 27 cases tumor GTVplanning
was delineated in the program Eclipse (Varian) and in 13 cases the
program Pinnacle (Philips) was used. The planning CT and the CT
part of the FAZA scan were automatically deformable fused using
SmartAdapt (Varian). GTVplanning from the planning CT was copied
to the FAZA PET/CT, generating a GTVFAZA-T. In a similar manner,
GTVFAZA-L of the previously delineated pathological lymph nodes
was produced, selecting the lymph node with the highest uptake
of FAZA. For the non-hypoxic reference tissue, a region of ﬁve con-
secutive slices was outlined in the neck muscle in the FAZA PET/CT
scan equivalent to a volume of 1.2 cm3 (mean). An in-house script
(MATLAB 7.12, The MathWorks Inc., Natick, MA, 2012) was used
to determine FAZA uptake in the GTVs and in the reference tissue.
Uptake was assessed as Standardized Uptake Values (SUV). To ver-
ify the SUV valuesmeasured byMATLAB, the tumor SUV for two pa-
tients was also determined by Eclipse and no difference was found.
Maximum, median, and mean SUV uptake of FAZA for the tumor
and lymph node (GTVFAZA-T and GTVFAZA-L) as well as mean and
median FAZA uptake in the reference tissue was determined. From
these values SUVmax in GTVFAZA-T divided by SUVmed in the muscle
Table 2
Relationship between FAZA uptake and HPV status.
FAZA PET data All patients HPV negative HPV positive P*
(n = 40) (n = 24) (n = 16)
Tmax/M
Median 1.5 1.5 1.7
Mean 1.7 1.7 1.8 n.s.
Range (1.1–2.9) (1.2–2.9) (1.1–2.9)
Tmed/M
Median 1.1 1.1 1.1
Mean 1.1 1.1 1.1 n.s.
Range (0.8–1.7) (0.8–1.6) (0.9–1.7)
HVP 1.4 (cm3)
Median 0.3 0.2 1.9
Mean 4.4 3.9 5.2 n.s.
Range (0.0–30.9) (0.0–30.9) (0.0–30.8)
FHVP 1.4 (%)
Median 2.8 1.0 13.6
Mean 15.9 13.7 19.1 n.s.
Range (0–91.7) (0–71.7) (0–91.7)
n.s., not signiﬁcant.
*
16 FAZA hypoxia imaging in radiotherapy treated HNSCC - DAHANCA 24(Tmax/M) and SUVmed in GTVFAZA-T divided by SUVmed in the muscle
(Tmed/M) were calculated. The procedure was similar for GTVFAZA-L.
In order to deﬁne a hypoxic volume (HV) in the tumors all vox-
els within GTVFAZA-T expressing a tumor-to-muscle value equal to
or above 1.4 was determined, creating HV. For each patient a his-
togram of FAZA SUV in the muscle (reference tissue) was obtained.
To compare these values each patient’s muscle histogram was nor-
malized by its own mean, resulting in all patients having a muscle
mean of 1. Subsequently all the histograms were pooled creating
one common muscle histogram. The standard deviation was 0.13,
hence a T/Mmean of 1.4 (mean + three standard deviations) was
set as the threshold. Consequently, more than 99% of the normal-
ized muscle values were below 1.4 in this material, the details
are described in Supplementary Fig. 1. In this study, hypoxic tu-
mors were deﬁned as tumors containing a hypoxic volume (HV),
whereas non-hypoxic tumors did not contain a hypoxic volume.
The procedure of deﬁning a HV was similar for GTVFAZA-L. Addition-
ally, the fractional hypoxic volume for the primary tumor (FHV)
was deﬁned as the HV divided by the entire GTVFAZA-T. The thresh-
old for hypoxia was selected blinded for patient outcome.Mann–Whitney–Wilcoxon test for comparison between HPV-negative and HPV-
positive groups.HPV data and analysis
Tumor HPV status was determined by immunohistochemical
detection of p16 which is a reliable surrogate marker for HPV infec-
tion in tumors [14]. Using antip16INK4A antibody clone JC8, as de-
scribed elsewhere [15], tumors were classiﬁed dichotomously as
either p16 positive (strong, diffuse nuclear and cytoplasmic stain-
ing in more than 70% of carcinoma cells) or p16 negative.15-Gene hypoxia classiﬁer
All 40 primary tumors were classiﬁed according to the 15-gene
hypoxia classiﬁer [16]. This classiﬁer has previously been able to
identify patients who had a signiﬁcant beneﬁt of hypoxic modiﬁca-
tion with nimorazole [17].35 24 7 38 37 3 2
3
20 8 34 17 16 2
2 39 9 6 27 11 2
5 5 15 1
3 33 3
0 4
0 1
9 2
6 4 2
9 31 2
1 14 3
2 2
12
28
1
18
36 10
0
10
20
30
H
yp
ox
ic
vo
lu
m
e
cm
0 10 20 30 40
Ranking
Non hypoxic, HPV-neg.
Hypoxic, HPV-neg.
Non hypoxic, HPV-pos.
Hypoxic, HPV-pos.
T-site failure
N-site failure
M-site failure
*
Fig. 1. Forty tumors ranked as a function of hypoxic volume. The hypoxic volume
was deﬁned by FAZA PET/CT imaging as all voxels within GTVFAZA-T expressing a
tumor-to-muscle value equal to or above 1.4. (⁄Patient ID 9 did not complete
treatment).Endpoints and statistics
The primary endpoint was loco-regional control after radiother-
apy deﬁned as complete and sustained disappearance of disease in
the T- and N-site. Secondary endpoints were disease free survival,
correlation of FAZA uptake in T-site and N-site, and correlation of
FAZAuptake at baseline compared to FAZAuptake during radiother-
apy. Time to event was estimated from the ﬁrst day of radiotherapy.
The closing date for analysiswas September 15, 2012. The studywas
designed to include 40 patients. This number was based upon pre-
vious studies, with a similar patient population using the Eppendorf
oxygen electrode or pimonidazole as prognostic hypoxic markers,
which have shown statistic signiﬁcant differences in loco-regional
control between patients with HNSCC [18,19].
Patient and tumor characteristics were compared with the Fish-
er’s exact test. FAZA PET characteristics were compared with the
Mann–Whitney Wilcoxon test. Correlation between FAZA uptake
in primary tumor and lymph node was tested using Spearman’s
rank correlation. Difference in outcome between the hypoxic and
the non-hypoxic group was estimated by Kaplan–Meier curves
and by log-rank test, stratiﬁed for HPV-status. P-values less than
0.05 were considered signiﬁcant. Analyses were performed with
the STATA statistical package, version 10 (STATA Corp, College Sta-
tion, TX).Results
FAZA uptake in the primary tumor
FAZA PET median HV varied considerably among all 40 tumors
with a range from 0.0 to 30.9 (median: 0.3) cm3; the FHV was
between 0 and 91.7 (median: 2.8)%. The Tmax/M was between 1.1
and 2.9 (median 1.5) and the median Tmed/M was 1.1 (range 0.8–
1.7), as shown in Table 2. Fig. 1 shows the ranking of the 40 tumors
according to the HV (ranking of the remaining quantiﬁcation meth-
ods can be seen in Supplementary Fig. 2). However, the shared
ranking within the 25 hypoxic tumors in FHV and Tmax/M was dif-
ferent from the ranking when using HV. The ranking of Tmed/M was
considerably different from the other quantiﬁcation methods, as
some of the 25 hypoxic tumors (as deﬁned by HV) had low values
of Tmed/M.Comparison between FAZA uptake and tumor characteristics
A hypoxic volume could be identiﬁed in 25 (63%) of the 40
tumors (Supplementary Fig. 3), whereas in 15 of the tumors all
tumor-to-muscle voxels were below 1.4. Patient and tumor charac-
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Fig. 2. Relationship between FAZA uptake in the primary tumor and the lymph
node is shown as a scatter plot. The correlation is positive (r = 0.517; P < 0.05). The
horizontal gray line shows the tumor-to-muscle threshold of 1.4 and the vertical
line the similar lymph node-to-reference threshold. Dark points illustrate patients
having a good correlation between the oxygenation status of the primary tumor and
a lymph node, as both are either hypoxic or non-hypoxic. The white points illustrate
discrepancy in the oxygenation status of the primary tumor and lymph node.
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There was no signiﬁcant difference between the hypoxic and
non-hypoxic tumors when accounted for age, gender, nodal stage,
tumor volume or tumor site. A signiﬁcant difference (p = 0.02) was
found between T classiﬁcation and FAZA hypoxic volume since
more T3–T4 tumors were represented in the hypoxic group.Relationship between FAZA uptake in primary tumor and lymph node
The relationship between FAZA uptake in the primary tumor
and the related lymph node could be compared in 30 patients, as
shown in Fig. 2. There was a positive correlation between maxi-
mum FAZA uptake in the primary tumor (Tmax/M) and the lymph
node of the same patient (Lmax/M), Spearman r = 0.517; p < 0.005.
However, when using the hypoxic volume to characterize tumors
and lymph nodes into hypoxic versus non-hypoxic a difference
was found in nine patients; eight patients had a hypoxic volume
in the primary tumor, but no hypoxic volume in the lymph node
and one patient (ID 26) had a hypoxic volume in a lymph node,
but no hypoxia in the primary tumor as seen in Fig. 2 (since this
patient have a hypoxic volume in the lymph node, but not in the
primary tumor, the hypoxic lymph node is subsequently consid-
ered as GTVFAZA_T). For 21 patients a match was found between
the lymph node and primary tumor.Repeated FAZA PET/CT imaging
Thirteen patients had two FAZA PET/CT scans separated by 14–
28 (median: 14) days. Nine patients of the thirteen had a hypoxic
volume at baseline. The median hypoxic volume for all thirteen pa-
tients was 0.3 (range 0–30.9) cm3 and the median Tmax/M was 1.6
(range 1.1–2.9). The majority of patients had no residual hypoxic
volume at the second FAZA PET/CT scan; the range of the hypoxic
volume was 0–20.2 (median 0) cm3 and the median Tmax/M was
1.4 (range 1.1–3.0). In six patients, hypoxic volumes could be de-
tected at the second scan. Though the HV was smaller, the location
remained stable in the tumors of these six patients, see Fig. 3. In
these six patients four had treatment failure (including one patient
with metastatic disease). Among the seven deﬁned as having noresidual hypoxia two treatment failures were found (one being
the patient who did not complete treatment).FAZA uptake and HPV
The HPV-positive and the HPV-negative tumors were found to
be equally hypoxic (Fig. 3), as no signiﬁcant difference was found
in the distribution of Tmed/M, Tmax/M, HV or FHV (Mann–
Whitney–Wilcoxon test), as seen in Table 2. When using the
threshold of HV to distinguish between hypoxic/non-hypoxic
tumors, 75% of the 16 HPV-positive tumors were hypoxic and
54% of the 24 HPV-negative tumors were hypoxic.FAZA uptake and the 15-gene hypoxia classiﬁer
The tumors were also ranked according to the expression of
genes included in the 15-gene hypoxia classiﬁer and separated in
two groups with 14 (35%) more hypoxic and 26 (65%) less hypoxic.
No correlation between hypoxic status, as assessed by the classiﬁer
and FAZA PET/CT imaging, was found (Supplementary Table 2).FAZA PET and outcome
Complete remission was detected in thirty patients. Potential
follow-up time, deﬁned as the time elapsed between the ﬁrst date
of radiotherapy and the closing date, ranged between 11 and 34
(median: 19) months. In 10 patients a treatment failure was de-
tected. Six patients had a recurrence at the primary tumor site,
two patients had a lymph node recurrence and two patients had
distant metastasis as veriﬁed by biopsies. Overall patients with
hypoxic tumors had a poorer outcome compared to patients with
non hypoxic tumors. Among the six patients with T-site recur-
rence, ﬁve had hypoxic tumors and one had a non-hypoxic tumor.
The latter patient, who did have a borderline hypoxic value of 1.3,
did not complete the radiotherapy treatment. The two patients
with distant metastases and the two with lymph node recurrence
both had hypoxic primary tumors. At the closing date ﬁve patients
had died, all with recurrence. One patient with T-site recurrence is
still alive after having received a salvage laryngectomy. The
remaining thirty patients are still alive with no sign of recurrence.
Fig. 1 shows tumor treatment failure within the ranking of HV.
All treatment failures, apart from one (who did not complete treat-
ment), where found among the hypoxic tumors. The actuarial 30-
month loco-regional control values were 93% and 66% (p = 0.07)
for patients with non hypoxic and hypoxic tumors, respectively.
However, the corresponding disease free survival values showed
a signiﬁcant difference in hypoxic and non hypoxic tumors (Fig. 4).
Discussion
A key point in hypoxia speciﬁc imaging is the evaluation meth-
od to differentiate hypoxic from non-hypoxic tumors. Typically a
tumor-to-background index is used. Based upon a certain thresh-
old the voxels within the tumor exhibiting a ratio value above
the threshold deﬁne a hypoxic volume (HV). Some studies using
FAZA imaging have used a qualitative measurement for FAZA up-
take [20], however, this method is highly dependent on the user
and the PET window settings, and hence it is not very reproducible.
Other studies have used a threshold based upon thresholds used in
FMISO imaging which typically range from 1.2 to 1.4. Since the
authors of those studies expected higher T/M ratios in FAZA PET
compared to FMISO the threshold for hypoxia was arbitrarily set
to 1.5 [21,22]. Using a threshold for deﬁning hypoxia is not biolog-
ically meaningful, since neither hypoxia nor tracer retention is a
dichotomic phenomenon. However, it illustrates that some tumors
contain more hypoxia than others.
Fig. 3. Top panel: Example of repeated FAZA PET/CT scans of a patient (ID 10) with oropharyngeal cancer. The red line illustrates the GTV. (A) The hypoxic volume (T/MP 1.4)
is 30.9 cm3 at baseline. (B) After 12 Gy the hypoxic volume has decreased to 13.7 cm3, but the localization remains stable. Bottom panel: FAZA PET/CT scans of patients with
tumors having a hypoxic volume (FAZA T/MP 1.4). (C) Male (ID 1) with a HPV-positive oropharyngeal cancer. (D) Male with a HPV-negative oropharyngeal cancer (ID 31).
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Fig. 4. Disease free survival of patients with hypoxic versus non hypoxic tumors as
assessed by FAZA PET.
18 FAZA hypoxia imaging in radiotherapy treated HNSCC - DAHANCA 24In this study, the threshold was selected based upon non-hyp-
oxic normal tissue. A neck muscle was used as the reference tissue,
as done in previous studies [21,22]. The threshold separating hy-
poxia from non-hypoxia was determined as three standard devia-
tions of the pooled normalized muscle values for all 40 patients.
More than 99% of the muscle voxels fell below 1.4. Consequently
the hypoxic volume within the tumor was deﬁned as all voxels
with a T/M equal to or above 1.4. Hence all tumors containing
one or more voxels with a value of 1.4 were identiﬁed as hypoxic.
In a previous study investigating small tumors (50 mm3), which
resembles the size of a voxel, higher doses were required for tumor
control in hypoxic compared to normoxic tumors [23]. The validity
of this threshold obviously requires correct delineation of the ref-
erence volume in the neck muscle and further conﬁrmation is war-
ranted. Of interest is the observation that the only patient with a
non hypoxic failure had a Tmax/M value of 1.3.
We have previously showed hypoxia assessed by FAZA PET is
prognostic for outcome in tumor bearing mice [24]. This is the ﬁrst
study to investigate the prognostic value of FAZA PET/CT imaging
in patients with HNSCC and we found FAZA PET/CT to be
prognostic for disease free survival in HNSCC. Signiﬁcant higher T
classiﬁcation was found among the hypoxic tumors. But the tumor
L.S. Mortensen et al. / Radiotherapy and Oncology 105 (2012) 14–20 19volume based upon CT was not different between the groups; con-
sequently in this study hypoxic status was independent of the vol-
ume of the tumor. To test the independent prognostic value of
FAZA PET/CT may require a multivariate analysis which is not be
possible due to the low number of events. Other clinical studies
have investigated the prognostic value of hypoxia speciﬁc imaging.
Generally these studies only include a small number of patients.
However, despite using different tracers, different types of
scannings (static/dynamic), various discriminators for identifying
the hypoxic tumors and different endpoints the results of these
studies are in line with our result; a tendency for a poor response
to radiotherapy for tumors that were hypoxic [25].
The hypoxic radiosensitizer nimorazole was given to all 40 pa-
tients, as this is part of the standard radiotherapy treatment for
HNSCC in Denmark. In a previous study by Nordsmark et al., with
a similar patient cohort also receiving nimorazole, a signiﬁcant dif-
ference between hypoxic and non-hypoxic tumors could be de-
tected [18] thus our study was designed accordingly but not
accounting for HPV status. HVP-positive tumors have a more favor-
able prognosis in terms of tumor control and survival compared to
HPV-negative cancers [14], and the incidence of these tumors is
rising. This was reﬂected in the current study as 16 of the tumors
were HPV-positive. As a consequence, the treatment outcome in
the DAHANCA 24 study is properly better than initially anticipated.
No correlation between HPV status and hypoxia was found in the
current study. Toustrup et al. showed some HPV-positive tumors
does express a hypoxia speciﬁc gene proﬁle, also indicating hypox-
ia can be present in these tumors as well as in the HPV-negative
tumors [17]. Nevertheless, one study found HPV-positive tumors
had a favorable prognosis regardless of hypoxic modiﬁcation [26]
presumably due to increased tumor radiosensitivity. In the current
study, two patients with hypoxic HPV-positive tumors experienced
treatment failure. Both had a history of smoking which is in line
with a study showing a poorer outcome in patients with HPV-
positive tumors and a smoking history as compared to patients
with HPV-positive tumors alone [27].
Overcoming hypoxia by dose painting is an intriguing concept.
Hypoxic cells are more radiation resistant; hence by increasing
the dose to hypoxic volumes of the tumor a higher tumor control
is expected [25]. As a result, some studies have investigated the
feasibility of dose painting a tumor based upon a hypoxia speciﬁc
PET scan and concluded that it is feasible [22,28], but whether it
will improve outcome remains to be proven [25].
In the present study, static FAZA PET/CT scans were used to
identify hypoxia. It is essential that FAZA only is retained in hyp-
oxic cells. This has previously been illustrated in an in vitro study
where FAZA uptake was found to be highly hypoxia speciﬁc and to
display little cell-to-cell type variability [29]. In accordance with
this, Busk et al. found a signiﬁcant positive correlation between
the spatial distribution of FAZA autoradiography and pimonidazole
(a well established exogenous hypoxia marker) in four different tu-
mor models [30]. Static scans 2 h after injection of FAZA were uti-
lized in this clinical study, although dynamic scans which allow
pharmacokinetic analysis arguably allow more accurate informa-
tion of hypoxia [31]. However, dynamic scans and kinetic modeling
are not feasible in a daily clinical setting.
In order to identify the hypoxic tumors a tumor-to-muscle
threshold was used, clearly identifying some tumors as being more
hypoxic than others. This threshold is entirely dependent on the
stability of the muscle reference, as a small change in the muscle
reference can lead to a considerable change in size of the hypoxic
volume. An additional challenge for dose painting is the day-
to-day stability of the hypoxia, which has been addressed previ-
ously. In one study repeated baseline FMISO imaging 3 days apart
showed a mismatch between the locations of intense FMISO up-
take for seven out of 13 patients [32]. However, in tumor-bearingmice a strong voxel-to-voxel correlation of FAZA PET could be
found in repeated baseline scans [33]. Also, the possible change
of location of hypoxia over the course of radiotherapy is essential
to investigate. Koh et al. showed a general decline in FMISO FHV
among patients with non small cell lung cancer in six patients,
but in one patient the FHV was higher at the end of treatment com-
pared to baseline [34]. In our study the repeated scans showed a
general decline in the hypoxic volume at the second scan com-
pared to the baseline hypoxia. Detectable hypoxia could be seen
within the tumor at the second scan in six patients, and generally
the location of the hypoxic volume remained stable. However, the
results are hampered by the small patient number, the variability
in time between scans and lack of voxel-to-voxel correlation.
Another challenge is the size of the PET voxel. A single PET voxel
may represent the average value of FAZA uptake in cells ranging
from anoxic to fully oxygenated with an unknown mixture of ne-
crotic tissue. Thus, as previously shown in pre-clinical models,
small regions of hypoxic cells can ‘hide’ within a non-hypoxic voxel
[35]. Consequently, PET imaging by FAZA and similar PET tracers
can describe hypoxia, but lack of uptake on a clinical PET scanner
does not necessarily equal lack of hypoxia. Hence, if a tumor con-
tains a hypoxic volume, dose boosting the entire tumor seems be
the appropriate strategy to assure all hypoxic cells are targeted
[25]. One modeling study concludes moderate dose escalations
may improve the tumor control probability [36] but this needs
clinical veriﬁcation [25].
The relationship between hypoxia as detected by FAZA PET/CT
imaging in a lymph node and the primary tumor was also investi-
gated in the present study. In the majority of patients there was
agreement between the detection of a hypoxic volume or lack
thereof, but in nine out of 30 patients there was no correlation be-
tween the two, when using the HV as the hypoxic discriminator.
This ﬁnding is in accordance with a previous PET study [37] and
emphasizes the importance of investigating both the primary tu-
mor and lymph node, since the hypoxia in a lymph node might
not be representative for the oxygenation status of the primary tu-
mor. However, a study using the Eppendorf electrode showed a
good correlation between the oxygenation status of a lymph node
and the primary tumor in patients [38], hence further studies
investigating this issue are needed.
In this prospective clinical study FAZA PET/CT imaging was uti-
lized to identify hypoxia in 40 patients with HNSCC receiving
radiotherapy. A large inter-tumor variability in FAZA uptake could
be detected and was associated with poor outcome in patients
with hypoxic tumors. This study emphasizes the role of FAZA
PET/CT imaging as a suitable assay with prognostic potential for
detection of hypoxia in HNSCC.Acknowledgements
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